109193 ⎘
Structure or type of the nucleic acid; Chemical structure; Nature of the modification Conjugate
Nucleic acids specifically binding CGRP
#1502Compounds and methods for enhanced cellular uptake
#1503Vitamin B6-coupled poly(ester amine) as gene carrier and application in cancer gene therapy
#1504Oligomer-conjugate complexes and their use
#1505Methods for Treating or Preventing Ophthalmological Conditions
#1506Methods and compositions involving miRNA and miRNA inhibitor molecules
#1507PREPARATION OF PNA-6-AMINOGLUCOSAMINE CONJUGATES AS ANTIVIRAL AGENTS
#1508Therapeutic nanoparticles and methods of use thereof
#1509SIRNA CONJUGATE AND PREPARATION METHOD THEREOF
#1510siRNA conjugate and preparation method thereof
#1511MicroRNA compounds and methods for modulating miR-122
#1512Serapina1 iRNA compositions and methods of use thereof
#1513Conjugated antisense compounds and their use
#1514Anti-FH aptamers, method for producing same, and uses thereof
#1515Selective antisense compounds and uses thereof
#1516Exon skipping compositions for treating muscular dystrophy
#1517Methods and compounds useful in conditions related to repeat expansion
#1518RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
#1519Targeted self-assembly of functionalized carbon nanotubes on tumors
#1520Site specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
#1521Therapeutic nanoparticles and methods of use thereof
#1522NGF aptamer and application thereof
#1523Modified siRNA molecules and uses thereof
#1524Method for evaluating redox activity of nucleic acid molecule and nucleic acid molecule having redox activity
#1525Compositions of matter that reduce pain, shock, and inflammation by blocking linoleic acid metabolites and uses thereof
#1526Nucleic acid modulators of glycoprotein VI
#1527Oligonucleotide derivative, oligonucleotide derivative-containing pharmaceutical composition for treatment and pharmaceutical composition for diagnosis, and oligonucleotide derivative for regulation of miRNA function
#1528Chimeric immunomodulatory compounds and methods of using the same-IV
#1529Methods of X-aptamer generation and compositions thereof
#1530Oligomeric compounds and compositions for use in modulation of small non-coding RNAS
#1531Modified iRNA agents
#1532Peptide-based in vivo siRNA delivery system
#1533Compositions and methods for inhibiting expression of the ALAS1 gene
#1534LAR protein-specific ligand
#1535Specific ligand for annexin 2
#1536Aptamer therapeutics useful in the treatment of complement-related disorders
#1537Ligand-conjugated monomers
#1538Oligonucleotide, and therapeutic agent for dyslipidemia containing oligonucleotide as active ingredient
#1539Reduced size self-delivering RNAi compounds
#1540Fractalkine binding polynucleotides and methods of use
#1541Nucleic acid functionalized nanoparticles for therapeutic applications
#1542COMPOSITIONS AND METHODS RELATED TO MIRNA MODULATION OF NEOVASCULARIZATION OR ANGIOGENESIS
#1543Modified oligonucleotides for telomerase inhibition
#1544Nucleic acid complexes
#1545Monomers and oligonucleotides comprising cycloaddition adduct(s)
#1546Double-stranded oligonucleotides
#1547Treatment of metastatic tumors
#1548SDF-1 binding nucleic acids
#1549APTAMER CELL COMPOSITIONS
#1550MCP-1 binding nucleic acids
#1551Oligonucleotide compounds comprising non-nucleotide overhangs
#1552Organic compositions to treat Beta-ENaC-related diseases
#1553Compositions and methods for inhibiting gene expression of hepatitis B virus
#1554Modified siRNA molecules and uses thereof
#1555Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
#1556Aptamer therapeutics useful in the treatment of complement-related disorders
#1557Low density lipoprotein receptor-mediated siRNA delivery
#1558Compositions and methods for preparing recombinant MG53 and methods for optimizing same
#1559Oligonucleotides which inhibit p53 induction in response to cellular stress
#1560CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS
#1561Structure and use of 5′ phosphate oligonucleotides
#1562Method of inhibiting miR-33 using a modified oligonucleotide
#1563Method for purifying active GLA-domain coagulation proteins
#1564Antisense molecules and methods for treating pathologies
#1565RNA-INTERFERENCE BY SINGLE-STRANDED RNA MOLECULES
#1566Oligonucleotide derivative comprising an aromatic compound
#1567Minor groove binder (MGB)-oligonucleotide miRNA antagonists
#1568Chimeric immunomodulatory compounds and methods of using the same-IV
#1569Polyconjugates for in vivo delivery of polynucleotides
#1570CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS
#1571Modified L-Nucleic Acid
#1572ANTIVIRAL OLIGONUCLEOTIDES
#1573Lipid formulation
#1574RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
#1575In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
#1576Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
#1577Peptide-based in vivo siRNA delivery system
#1578Compositions and methods for inhibiting expression of RRM2 genes
#1579Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#1580Particles with multiple functionalized surface domains
#1581MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION
#1582Organic compositions to treat Beta-ENaC-related diseases
#1583Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#1584Ghrelin binding nucleic acids
#1585Organic compositions to treat beta-ENaC-related diseases
#1586Organic compositions to treat Beta-ENaC-related diseases
#1587siRNA conjugate and preparation method thereof
#1588Oligomers
#1589Oligomers
#1590DOUBLE-STRANDED OLIGONUCLEOTIDES
#1591METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES
#1592Methods for treating hypercholesterolemia
#1593Methods and compositions involving miRNA and miRNA inhibitor molecules
#1594Oligomers
#1595Polymeric nano-particles for siRNA delivery using charge interaction and covalent bonding
#1596Hepcidin binding nucleic acids
#1597NUCLEIC ACIDS SPECIFICALLY BINDING WITH HUMAN FACTOR VII/VIIA AND USES THEREOF
#1598Method for inhibiting the activity of mir-155
#1599FOLATE TARGETING OF NUCLEOTIDES
#1600Phagocytic cell delivery of RNAI
#1601Viral Therapy and Prophylaxis Using Nanotechnology Delivery Techniques
#1602COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION
#1603LNA ANTAGONISTS TARGETING THE ANDROGEN RECEPTOR
#1604METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES
#1605Oligomeric compounds and methods
#1606RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#1607RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#1608PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING
#1609RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#1610Organic compositions to treat beta-ENaC-related diseases
#1611CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND SMALL MOLECULES FOR USE IN REDUCING MICRO RNA ACTIVITY LEVELS AND USES THEREOF
#1612Low density lipoprotein receptor-mediated siRNA delivery
#1613Nanoparticle-based gene delivery systems
#1614Oligomeric compounds and compositions for use in modulation of small non-coding RNAS
#1615SDF-1 binding nucleic acids and the use thereof
#1616Inhibition of HRP-3 using modified oligonucleotides
#1617RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
#1618ANTISENSE RESTENOSIS COMPOSITION AND METHOD
#1619Minor groove binder (MGB)-oligonucleotide miRNA antagonists
#1620RNA COMPOSITIONS FOR MODULATING IMMUNE RESPONSE
#1621Methods for treating androgen receptor dependent disorders including cancers
#1622Diblock copolymers and polynucleotide complexes thereof for delivery into cells
#1623RNAi-mediated inhibition of tumor necrosis factor α-related conditions
#1624Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
#1625Cationic siRNAs, synthesis and use for RNA interference
#1626SDF-1 binding nucleic acids
#1627Compositions and methods for inhibiting expression of anti-apoptotic genes
#1628POLYMERIC SYSTEMS CONTAINING INTRACELLULAR RELEASABLE DISULFIDE LINKER FOR THE DELIVERY OF OLIGONUCLEOTIDES
#1629Compounds for the modulation of beta-catenin expression
#1630Lipid encapsulating interfering RNA
#1631Modulation of apolipoprotein C-III expression
#1632Aptamer therapeutics useful in the treatment of complement-related disorders
#1633METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA
#1634Lipid formulation
#1635Nucleic acid modulators of glycoprotein VI
#1636MicromiRs
#1637IMMUNOTHERAPY COMPOSITIONS, METHOD OF MAKING AND METHOD OF USE THEREOF
#1638MCP-1 binding nucleic acids
#1639Combination treatment for the treatment of hepatitis C virus infection
#1640COMPOSITIONS COMPRISING HIF-1 ALPHA SIRNA AND METHODS OF USE THEREOF
#1641POLYMERIC SHORT INTERFERING RNA CONJUGATES
#1642Method for inhibiting the activity of mir-155
#1643Oligomeric compounds and compositions for use in modulation of pri-miRNAs
#1644LNA antagonists targeting the androgen receptor
#1645Hindered ester-based biodegradable linkers for oligonucleotide delivery
#1646RNAi inhibition of alpha-ENaC expression
#1647RNAi inhibition of alpha-ENaC expression
#1648RNAi inhibition of alpha-ENaC expression
#1649RNAi inhibition of alpha-ENaC expression
#1650Modulators of coagulation factors
#1651Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
#1652Antisense compounds
#1653RNAi inhibition of alpha-ENaC expression
#1654Compositions of TLR ligands and antivirals
#1655Multifunctional nucleic acid nano-structures
#1656STRUCTURE AND USE OF 5'PHOSPHATE OLIGONUCLEOTIDES
#1657ANTIVIRAL OLIGONUCLEOTIDES TARGETING RSV
#1658ANTIVIRAL OLIGONUCLEOTIDES TARGETING VIRAL FAMILIES
#1659Oligomers
#1660RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS
#1661DOUBLE-STRANDED OLIGONUCLEOTIDES
#1662Polyvalent RNA-nanoparticle compositions
#1663Modified L-Nucleic Acid
#1664Chemically modified oligonucleotides
#1665CYCLODEXTRIN CONJUGATES
#1666Carrier nanoparticles and related compositions, methods and systems
#1667Platelet derived growth factor (PDGF) nucleic acid ligand complexes
#1668Long interfering nucleic acid duplexes targeting multiple RNA targets
#1669TOLL-LIKE RECEPTOR 9 AGONISTS
#1670Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
#1671Methods for treating hypercholesterolemia
#1672Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#1673Compositions and Methods to Monitor RNA Delivery to Cells
#1674Chimeric immunomodulatory compounds and methods of using the same-II
#1675ENCAPSULATED NANOPARTICLES FOR DRUG DELIVERY
#1676CONJUGATED DOUBLE STRAND COMPOSITIONS FOR USE IN GENE MODULATION
#1677Immuno-RNA-constructs
#1678Treatment of metastatic tumors
#1679Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#1680Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#1681Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#1682Ligand-conjugated monomers
#1683Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs
#1684MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION
#1685Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
#1686Modified siRNA molecules and uses thereof
#1687CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
#1688Biotinylated compositions
#1689COMPOSITIONS AND METHODS FOR REGULATING GENE TRANSCRIPTION
#1690Nucleic acid functionalized nanoparticles for therapeutic applications
#1691Compounds for the modulation of beta-catenin expression
#1692Glycoconjugates of RNA interference agents
#1693GENE THERAPY FOR CANCER USING SMALL INTERFERING RNA SPECIFIC TO ANT2 AND A METHOD TO OVERCOME TOLERANCE TO ANTITUMOR AGENT
#1694LNA antagonists targeting the androgen receptor
#1695Vasopressin-binding L-nucleic acid
#1696Methods and compositions involving miRNA and miRNA inhibitor molecules
#1697STEADY-STATE SUBCUTANEOUS ADMINISTRATION OF APTAMERS
#1698RNAi inhibition of alpha-ENaC expression
#1699Antiviral oligonucleotides targeting viral families
#1700MicroRNAs
#1701Ladder copolymers
#1702Tripartite RNAi constructs
#1703LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERY
#1704Stabilized Aptamers to PSMA and Their Use as Prostate Cancer Therapeutics
#1705Antiviral oligonucleotides
#1706Oligonucleotide analogs having cationic intersubunit linkages
#1707Metabolic profile directed aptamer medicinal chemistry
#1708FINE PARTICULATE PREPARATION COMPRISING COMPLEX OF NUCLEIC ACID MOLECULE AND COLLAGEN
#1709Compositions and methods for inhibiting expression of anti-apoptotic genes
#1710Stabilized Aptamers to Platelet Derived Growth Factor and their Use as Oncology Therapeutics
#1711Antiviral oligonucleotides targeting HBV
#1712RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#1713Double-Stranded Oligonucleotides
#1714Nucleic Acid Ligands Specific to Immunoglobuline E and Their Use as Atopic Disease Therapeutics
#1715COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION
#1716Nucleic acid based ladder copolymers
#1717METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA
#1718Nucleic acid functionalized nanoparticles for therapeutic applications
#1719Methods of nonspecific target capture of nucleic acids
#1720Nanoparticles Comprising Rna Ligands
#1721Platelet derived growth factor (PDGF) nucleic acid ligand complexes
#1722Nucleic Acid Complex
#1723Chimeric immunomodulatory compounds and methods of using the same
#1724Methods and compositions involving miRNA and miRNA inhibitor molecules
#1725Methods and compositions involving miRNA and miRNA inhibitor molecules
#1726Modulators of coagulation factors
#1727Modulators of coagulation factors with enhanced stability
#1728Compositions and methods for the treatment of muscle wasting
#1729Peptide Nucleic Acid Conjugates and Uses Thereof
#1730Cytoplasmic Localization Dna and Rna
#1731Conjugate of Peo and Double Stranded Nucleic Acid
#1732Methods and compositions involving miRNA and miRNA inhibitor molecules
#1733Polycationic compositions for cellular delivery of polynucleotides
#1734Immunostimulatory oligonucleotides
#1735SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
#1736RNAI-mediated inhibition of tumor necrosis factor α-related conditions
#1737CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY
#1738Antisense restenosis composition and method
#1739Activatable Ribozymal Purification Constructs and Methods of Use
#1740METHODS OF TREATING AND MONITORING SYSTEMIC LUPUS ERYTHEMATOSUS IN INDIVIDUALS
#1741Hedgehog Kinases and Their Use in Modulating Hedgehog Signaling
#1742RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#1743Nucleotide sequences promoting the trans-membrane transport of nucleic acids
#1744RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA)
#1745Detection, monitoring and treatment of cancer
#1746Modified siRNA molecules and uses thereof
#1747Modulators of coagulation factors with enhanced stability
#1748Aptamer medicinal chemistry
#1749Chimeric immunomodulatory compounds and methods of using the same—IV
#1750Methods for use in modulating miR-122a
#1751Substituted, non-coding nucleic acid molecule for therapeutic and prophylactic stimulation of the immune system in humans and higher animals
#1752Conjugate for gene transfer comprising oligonucleotide and hydrophilic polymer, polyelectrolyte complex micelles formed from the conjugate, and methods for preparation thereof
#1753Methods and compositions for treatment of tumors using nucleic acid ligands to platelet-derived growth factor
#1754Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
#1755RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#1756RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#1757RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#1758RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#1759Vectorization of dsRNA by cationic particles and topical use
#1760RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#1761RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#1762Methods and compositions for treating ocular disorders
#1763RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#1764RNA interference mediated ihibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#1765RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#1766RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#1767RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#1768Modulation of apolipoprotein c-III expression
#1769Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
#1770Ghrelin binding nucleic acids
#1771Oligomeric compounds and compositions for use in modulation of pri-mirnas
#1772RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#1773RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#1774Oligonucleotide mimetics
#1775RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
#1776RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#1777RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#1778RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#1779RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#1780Immunostimulatory oligonucleotides
#1781Methods of down regulating target gene expression in vivo by introduction of interfering rna
#1782Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
#1783Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
#1784Treatment of mycobacterium tuberculosis with antisense oligonucleotides
#1785Method of spotting probes on a solid support
#1786RNA-interference by single-stranded RNA molecules
#1787Antiviral oligonucleotides
#1788Conjugates of photosensitizers and oligonucleotides for selective photochemiotherapy
#1789Compositions and methods for inhibiting expression of anti-apoptotic genes
#1790Devices coated with substances which mediate the adhesion of biological material
#1791Omega-amino-PEG-phosphoramidites and conjugates thereof
#1792Chemically modified oligonucleotides
#1793Modulators of coagulation factors
#1794Controlled modulation of the pharmacokinetics and biodistribution of aptamer therapeutics
#1795Aptamer therapeutics useful in the treatment of complement-related disorders
#1796Double-stranded oligonucleotides
#1797Lipid encapsulated interfering RNA
#1798Control of gene expression via light activated RNA interference
#1799Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
#1800Novel 38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, FBH58295FL, 57255, and 57255alt molecules and uses therefor